Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU

What Was Tested

In this phase 2 trial, researchers set out to test Vasopressin.

It had two arms (groups): Vasopressin (experimental) and Placebo (placebo comparator).

The registry classes the interventions as drug and other.

More on the Plan

This is a multicenter, placebo-controlled, double-blind, randomized feasibility clinical trial with a proposal to include 60 patients across 3 to 4 research centers.

The primary objective is to evaluate the feasibility of the study, specifically adherence to the established protocol and the monitoring of potential adverse effects during its conduct.

Who Took Part

The registry lists 60 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adult patients (≥18 years old);. Admitted to intensive care units;.

The full record lists 3 inclusion and 12 exclusion criteria; among the exclusions: time since admission to the icu greater than 24 hours;; use of vasopressors at the time of inclusion;; MAP \>90 mmHg;.

How the Study Was Run

Design: randomized, parallel-group and quadruple-blind.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Vasopressin group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2025-04-10 with completion listed for 2025-10-10.

It ran at 1 site in Brazil.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Feasibility (time frame: 6 months).

It also tracked 1 secondary outcome, for example Creatinine, in mg/dL.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Vasopressin in 60 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Vasopressin compound page, all human trials.